BioSpace News Archive

The report highlights trends prevailing in the miRNA sequencing and assay market along with the factors governing its growth.

Assure Holdings Corp., a provider of intraoperative neuromonitoring services, is pleased to announce that it supported a successful auditory brainstem implant surgery.

Updated Data Show Median Overall Survival of 35.4 Weeks in Patients Treated With Combination Therapy for at Least One Month – Median Overall Survival in Relapse/Refractory Patients with Standard of Care is Approximately 28 weeks

Kineta, Inc. announced today that Thierry Guillaudeux, Ph.D., SVP Immuno-oncology at Kineta, participated on multiple panel presentations during the virtual symposium “VISTA: A New Immune Checkpoint in Cancer, Autoimmunity and Beyond.”

Nucleai (www.nucleaimd.com), and Merck KGaA, Darmstadt, Germany, announced that they have entered into a long-term collaboration to leverage Nucleai’s image analysis and biomarker discovery platform for several Merck KGaA, Darmstadt, Germany clinical stage oncology assets.

The molecular quality controls market is expected to reach US$ 372.64 million in 2028 from US$ 184.62 million in 2021; it is estimated to grow at a CAGR of 10.6% during 2021–2028.

4D Molecular Therapeutics announced an update on their rare disease ophthalmology product candidate portfolio including Phase 1 dose escalation clinical trial.

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced the initiation of a Phase 1b clinical trial of VK0214, a novel small molecule agonist of the thyroid hormone receptor beta, in patients with X-linked adrenoleukodystrophy.

Navidea Biopharmaceuticals, Inc. , today announced that on June 23, 2021, Vice Chancellor Joseph Slights of the Court of Chancery of the State of Delaware (the “Court”) ruled in favor of Navidea’s wholly-owned subsidiary, Macrophage Therapeutics, Inc.

GenapSys, Inc. today announced the additions of Britton Russell , Mary Stewart , and Surekha Karudapuram to its executive team.